Translate

Monday, December 26, 2016

Making Lemonade Out of Lemons

                                        Making Lemonade Out of Lemons
By Albert B. Kelly

Recently in this very space, I did a little riff on the idea that elections have consequences. I was referring to the fact that the President-elect has nominated Tom Price, a House member from Georgia to be the new Health and Human Services Secretary.

That nomination troubled me, because if he has his way, Price may well push a plan to turn Medicare into a block grant that would be turned over to the states to run.

That means that each state would get a chunk of money to administer Medicare at the state level, though overall Medicare funding itself would be cut a great deal in the process.

For the record, Medicare is the federal health insurance program for people who are 65 or older and younger people with certain disabilities and chronic medical conditions.

If Medicare is turned over to the states as a block grant, one thing we should absolutely insist on is the ability of states join together to negotiate drug prices with the pharmaceutical companies. Why is this important you ask?

It’s important because right now, Medicare, which the largest purchaser of drugs in the world, is prohibited by law from negotiating drug prices with the pharmaceutical companies.

Congress in its infinite wisdom passed a law ensuring that Medicare has to pay 106% of what the drug companies’ claim is the “average wholesale price” of whatever drug they’re peddling. Behold the power of big Pharma and campaign contributions. 

According to the research done by journalist and author Steven Brill for his book “Bitter Pill” which is about our messed up health care system, this little nugget costs us about $40 billion a year.

Without this law preventing Medicare from negotiating with drug companies, we would pay roughly the same prices as Canada and they pay anywhere from 30% to 50% less than we do for the same exact meds.

Congress also killed legislation that would have allowed Americans to buy drugs from Canada- the drug companies lobbied hard against this so as to protect their profits.

I mention all of this to say that if the new administration is going to cut funding for Medicare, turn it into a block grant and give it over to the states to handle, they should let the states- whether individually or collectively- negotiate with the drug companies to get the best prices.

Regardless of whether the feds or the states administer Medicare, we shouldn’t have to pay 106% of the “average wholesale price”- a number that we’re forced to take as a matter of faith from the very companies getting rich off of our illnesses and surgeries and diseases.

When pressed as to why they need us to pay so much money, Big Pharma tells us it’s to continue research and development of the very wonder-drugs that treat our ailments. Fair enough, but what happened to competition and why are we doing the heavy lifting for the rest of the world?

If Medicare is turned over to the states as a block grant, New Jersey should be allowed to negotiate drug prices with manufacturers. And if we don’t have enough bargaining power on our own, we should be able to team up with Delaware, New York, or Pennsylvania to negotiate as a regional block.

With Medicare being the largest purchaser of drugs in the world, that’s a powerful negotiating position that would help to drive down the costs of meds in this country. It would also level the playing field.

But it can only happen if New Jersey can join up with other states to flex our collective muscle in the market place. I’m not in favor of cutting Medicare funding and block-granting over to the states to run.

But if it has to happen- this block granting thing, if this is the lemon we get, then we should at least be allowed to see if we can get a little lemonade out of the darned thing.

Just a little lemonade in the form of allowing states to join as regional negotiating blocks to haggle prices with the drug companies or at least allow Americans to buy their meds at cheaper prices from Canada or wherever.

There was much talk this election cycle about “draining the swamp”. Regardless of how things go anywhere else, if Congress continues to prevent Medicare from negotiating with the drug companies, then it’s a safe bet that the swamp is still alive and well.